Candel Therapeutics Sets Path to Success

Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

• Approaching 6 anticipated data readouts across 3 platforms in 2024, including survival data in non-small cell lung cancer (NSCLC) and a potentially registrational phase 3 clinical trial in prostate cancer
  
• Focusing on strategic key value drivers and catalysts, as a follow up to positive initial clinical and biomarker data in hard-to-treat cancers
• Advancing the immunotherapy field with next-generation investigational therapies at the intersection of advanced analytics, biology and vectorology
• Executing on goal for operational excellence and efficiency, as evidenced by company’s recent program prioritization

NEEDHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's immunotherapy portfolio and provided updates on multiple upcoming milestones.

“Candel is innovating a new frontier in immunotherapy, backed by promising clinical and biomarker data in hard-to-treat indications with six data readouts expected this year,” said Paul Peter Tak, MD PhD FMedSci, President and CEO of Candel. “Candel is focused on delivering key value drivers to maximize the impact of its assets and to create substantial value to patients and other stakeholders. In 2023, we received Fast Track Designation from the FDA for CAN-2409, our most advanced product candidate, for both NSCLC and pancreatic cancer. Clinical data from the ongoing phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma have recently been published in Nature, which further supports the scientific and clinical excellence of Candel’s programs.”

Dr. Tak continued: “Beyond our promising drug candidates that are being tested in the clinic, the novel enLIGHTEN Discovery Platform has already demonstrated the capability to generate experimental candidates, expanding Candel’s potential to create value through novel collaborations to develop treatments for diverse types of cancer. We are excited for our upcoming clinical and scientific readouts in 2024.”

2024 Anticipated Data Readouts and Key Catalysts:

Candel plans to announce 6 anticipated readouts across its 3 platforms in 2024, which include novel clinical and biomarker data in lung cancer, pancreatic cancer, brain cancer and a potentially registrational phase 3 clinical trial in prostate cancer.